Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.
The effects of prolonged treatment with glyclazide [methyl-4-fenyl sulfonyl-1(perhydrocyclopenta(c) pyrrolyl-2)-3 urea] on blood glucose and plasma insulin responses to meals was studied in 8 obese patients with maturity-onset diabetes. Blood sampling was done 1 hr after meals for 2 consecutive days, on days 10 and 90 of therapy. Lower blood glucose curves were achieved on both days 10 and 90 in all patients. Plasma insulin curves in response to meals were higher than control on both days 10 and 90. The results may suggest that the long-term effect of glyclazide on blood glucose is related to a persistent stimulation of insulin secretion rather than to a predominant extrapancreatic action.
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005907:Gliclazide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D005907:Gliclazide